The aims of the study were to characterize the pharmacokinetics (PK) of selumetinib (AZD6244; ARRY-142886), a mitogenactivated protein kinase kinase (MEK) 1/2 inhibitor in clinical development for various indications, and its N-desmethyl metabolite in healthy volunteers, and evaluate clinically important covariates.
Introduction
To maintain their malignant phenotype, cancer cells are dependent on the activating mutations of the mitogenactivated protein kinase pathway [1] . Selumetinib (AZD6244, ARRY-142886) is an oral, potent and selective, allosteric mitogen-activated protein kinase kinase (MEK)1/2 inhibitor [2] with a short half-life [3, 4] . In preclinical studies, selumetinib effectively inhibited extracellular signal-regulated kinase (ERK) phosphorylation and suppressed tumour proliferation in human melanoma-bearing nude mice [4] . Selumetinib also inhibited acquisition of the breast cancer stem cell phenotype and prevented lung metastasis of triple-negative breast cancer in a xenograft model [5] .
In clinical studies, inhibition of ERK phosphorylation by selumetinib has been demonstrated in peripheral blood mononuclear cells and lymphocytes in patients with advanced cancers [3, 6] , and the magnitude of inhibition of ex vivo 12-O-tetradecanoylphorbol-13-acetate-induced ERK phosphorylation in lymphocytes was related to selumetinib plasma concentrations [3] . Selumetinib is under clinical development in a number of indications, including differentiated thyroid cancer [7] and neurofibromatosis type 1 [8] .
The pharmacokinetics (PK) of selumetinib have been evaluated both in healthy subjects and patients with various tumours [3, 6, 9, 10] . Approximately dose-proportional PK were observed for selumetinib doses up to 100 mg twice daily [3, 6] , and 75 mg twice daily was established as the maximum tolerated dose for selumetinib [3] . The apparent oral clearance of selumetinib ranges from 12.1 l h -1 to 23.2 l h -1 in patients with advanced cancer [3] . Selumetinib is metabolized by cytochrome P450 (CYP) 1A2, 2C19, 3A4 and 3A5 and direct glucuronidation. Results from preclinical studies following administration of oral and intravenous (IV) selumetinib indicate that biliary clearance may play an important role in drug elimination (unpublished data on file, AstraZeneca, UK). The active metabolite, N-desmethyl selumetinib, is approximately three to five times more potent than selumetinib, and circulates at about 10% of the selumetinib concentration in the plasma [11, 12] . The N-desmethyl metabolite is generated primarily by CYP1A2 and metabolized through the same routes as selumetinib. Selumetinib and N-desmethyl selumetinib show weak CYP2C9 and 1A2 inhibition, and low potential for induction at clinically relevant concentrations. In vitro studies also indicate that selumetinib is a substrate of P-glycoprotein and Breast cancer resistance protein (unpublished data on file, AstraZeneca, UK).
Selumetinib drug-drug interactions (DDIs), bioavailability, food effects, and hepatic and renal impairment effects have been evaluated in multiple clinical pharmacology studies [10] [11] [12] . The objectives of the current analysis were to develop a population PK model of selumetinib and its N-desmethyl metabolite in healthy subjects, following oral and IV administration of selumetinib, and to evaluate the influence of covariates on the population PK parameters of selumetinib and N-desmethyl selumetinib.
Methods

Data
The PK of selumetinib and N-desmethyl selumetinib were evaluated from 10 phase I clinical studies with healthy volunteers or subjects with hepatic or renal impairment (summarized in Table 1) .
In all studies, subjects were given a single dose of selumetinib, followed by PK sample collection. A crossover design was utilized in six of the 10 studies, with subjects receiving selumetinib on 2-4 occasions, with each dose separated by a washout period of at least 7 days. Most subjects received selumetinib as the standard phase III capsule formulation of the hydrogen sulphate salt. Variants of the selumetinib capsule investigated in Study 78 were omitted from the analysis dataset as they did not meet the dissolution criteria and were not carried forward for clinical development. PK data obtained from the investigation of earlier selumetinib (phase II capsule and solution) formulations in Study 66 were retained for the population analysis. Subjects in Study 80 received a single oral dose of 75 mg selumetinib followed by 80 μg [ 14 C] selumetinib, administered as an IV microdose 15-min infusion starting 1 h 15 min after receiving the oral dose. For DDI studies, the interacting drug was allowed to reach steady state levels prior to investigating the effects on selumetinib exposure. The studies were conducted in accordance with all regulatory and Good Clinical Practice guidelines. All clinical studies were approved by the appropriate ethics committees, and written informed consent was obtained from all the subjects prior to their enrolment.
Bioanalysis
Plasma samples were analysed using a validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) method over a concentration range of 2-2000 ng ml -1 for selumetinib, and 2-500 ng ml -1 for N-desmethyl selumetinib.
The within-and between-batch precision [coefficient of variation (CV%)] and accuracy [relative standard error (RSE%)] for parent and metabolite were within the acceptable limit threshold of ±15%, and the lower limit of quantification was 2 ng ml -1 [13] .
Population PK modelling
General modelling approach. Owing to the multitude of variables arising from the pooling of so many PK studies, a systematic approach was implemented for an efficient and logical model-building strategy. In the first instance, all studies (excluding Studies 78 and 80 as these were unavailable at the point of analysis) were pooled to inform the underlying structural model for the time-concentration profile of selumetinib. Studies 66 (formulation) and 69 (food effects) were also analysed individually to: (i) ascertain whether the same structural model was suitable for all formulations and fed conditions; and (ii) to understand any differences in absorption and relative bioavailability within each study. Formulation or food effects previously determined to be significant were incorporated into the base model a priori.
The DDI effects of all tested compounds on selumetinib PK have been previously investigated (noncompartmental analyses [12] ), and were thus added to the base model a priori. A model-based covariate analysis within the parent base model was subsequently carried out. Model development later progressed to encompass simultaneous modelling of all parent and metabolite concentration data. Data from Studies 78 and 80 were used to update the developed parent and joint models as they became available.
Model development. The population analysis was conducted using nonlinear mixed-effects modelling in NONMEM® version 7.3 (Icon Development Solutions, Ellicott City, MD, USA) using the conditional first-order approximation (with interaction) method [14] . Data preparation, graphical analysis, model diagnostics and statistical summaries were all performed within R version 3.1.0 [15] . To account for the difference in molecular weight between selumetinib and N-desmethyl selumetinib, concentrations for each analyte were converted to nanomoles per litre prior to analysis. Concentrations reported as below the lower limit of quantification were omitted. Based on the visual examination of PK profiles and previous experience with modelling selumetinib and its N-desmethyl metabolite, one-and two-compartment linear models were fitted to the parent, and a one-compartment model to the metabolite for the joint modelling. Selection of the structural model and residual error models was based on goodness-of-fit plots and on the difference in NONMEM® objective function value (OFV). Other criteria that were used to discriminate between two models included the interindividual variance (ω 2 ), residual variance (σ 2 ), precision in parameter estimation (RSE%), precision in estimates of coefficients [95% confidence intervals (CIs) for estimates do not contain 0] and correlations between parameters. Finally, parameter estimate values were assessed relative to current knowledge of the compound. The interindividual variability (IIV) in population parameters was assumed to be log normally distributed and was estimated as follows:
Where P i is the estimated parameter in the i th individual,
PV is the population mean value predicted by the regression model and η i , P is the random variable assumed to be normally distributed with variance ω 2 and a mean of zero.
The residual error was modelled in the log domain using either an additive or a combined additive and proportional error model as follows:
where Cij is the observation in individual i at timepoint j,Ĉ ij is the model-predicted value in individual I at timepoint j, and M is an estimated positively constrained parameter. ε pij and ε aij are residual proportional and additive random errors, assumed to have zero mean and variance, σ 2 .
Covariate analysis. The covariates to be screened were selected a priori and included weight, age, ethnicity, renal function status (pre-and postdialysis), Child-Pugh score, and aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin and bilirubin levels. For continuous covariates, scatter plot correlation matrices were used to examine the distribution of covariates and the nature of covariate-PK parameter relationships, and to identify the presence of colinearity among covariates. For covariates that are categorical in nature, box-and-whisker plots of PK parameters were used to aid in the identification of differences between groups. Covariates were evaluated by a stepwise forward inclusion and backward exclusion process to the base model [16] . A covariate was only retained in the model if the OFV increased by more than 10.83 points (α = 0.001, 1 df) on its removal. The effect of continuous covariates on structural model parameters was modelled as follows:
where θ 1 is the population mean parameter, θ i is the individual parameter and θ 2 is the proportionality constant, intersect or the power parameter relating the clinical or demographic characteristics to the population model parameter. The median covariate is the median value within the population. Discrete variables such as comedication and race were modelled as follows:
where 'Factor' is an indicator with a value of either one or zero when the assumption made for the covariate under investigation is true or false.
Model evaluation and sensitivity analysis. Various diagnostic plots and visual predictive checks, stratified by study and cohort where appropriate, were used to evaluate model performance [17] . A sensitivity analysis was performed using the final joint population PK model to evaluate the impact of each identified significant covariate (univariately) on PK parameters [area under the concentration-time curve from zero to 72 h (AUC Population pharmacokinetics of selumetinib in healthy volunteers below the limit of quantification for selumetinib and N-desmethyl metabolite, respectively, were excluded. The age and weight of subjects ranged between 18 years and 66 years (median 30 years), and 51 kg and 123 kg (median 77 kg), respectively. The distribution of race among subjects was as follows: Caucasian (48.0%), Black (29.8%), Japanese (7.8%), Indian (3.2%), Chinese (2.0%), other (0.6%) and Asian other (8.7%). The majority of subjects were male (95%) ( Table 2) .
Parent model
The parent model comprised two compartments, with input of drug via sequential zero-first order, delayed absorption and linear elimination from the central compartment. A number of input models were tested as alternatives, of which sequential absorption gave the best fit of the observed data. IIV was estimated on apparent drug clearance (CL/F), apparent volume of distribution of the central compartment at steady state (V2/F), apparent volume of distribution of the peripheral compartment at steady state (V3/F), duration of zero-order absorption (D1) and lag time, and a covariance term was estimated for CL/F and V2/F. Interoccasion variability was investigated during model development but could not be estimated. An additive error model in the log domain was used to describe the intraindividual variability, with a separate error term for when the time after dose was less than 3 h and greater than 3 h, thereby enabling the magnitude of error associated with the absorption process to be separated from the error associated with the disposition processes.
No difference in relative bioavailability between formulation types (phase II capsule vs. phase III capsule vs. solution) was detected following the population PK analysis of Study 66 data alone. However, selumetinib as the Captisol® oral solution exhibited a more rapid absorption phase compared with the capsule formulations with an approximate lag of 0 h. The results from the population PK analysis of Study 69 alone indicated a statistically significant difference in D1 and relative bioavailability between fasted and fed states. The inclusion of food and formulation effects into the base model resulted in a significant reduction in the OFV of 711 units. In the next stage, the effects of DDIs (rifampicin, fluconazole and itraconazole) on selumetinib CL were incorporated into the model (ΔOFV, À1843). In the final stage of base model development, weight was included on CL/F and V2/F using fixed exponents of 0.75 and 1.00, respectively (ΔOFV, À52), to delineate the effects of body size from other covariate influences such as race. Correlations between body weight and CL/F or V2/F were no longer apparent in scatter plots following the incorporation of these exponents.
Covariate analysis identified bilirubin (ΔOFV, À32) and race [Japanese (JAP) and non-Japanese (NJAP) groups; ΔOFV, À37] to be statistically significant determinants of CL/F, and age (ΔOFV, À29) was the only influential covariate on V2/F. The Child-Pugh score was a significant covariate for CL/F during univariate analysis, but as covariate model development progressed it was no longer found to be predictive. No covariates were found to affect the V3/F parameter. In the final model presented below, selumetinib clearance is described as a function of weight, bilirubin, race (JAP and NJAP in equation below) and whether there is comedication with fluconazole, itraconazole or rifampicin. V2 is given as a function of weight and age.
The covariate model that was developed was updated with data from Studies 78 and 80 in a step-wise manner. The demographics and clinical characteristics of subjects from these additional studies were similar to those of the rest of the population. Parameter estimates did not change significantly following the addition of data from Study 78, and changes observed in PK estimates following the inclusion of Study 80 (oral and IV) data were reflective of the estimated oral bioavailability for selumetinib (F = 0.69).
All fixed-and random-effect parameters within the final model were estimated with acceptable precision (Table 3) . CL was inversely proportional to bilirubin level, and modelling using a linear relationship suggested a 9% decrease in CL from the population value for each unit rise in bilirubin concentration. Japanese and non-Japanese Asian subjects were estimated to have a reduced CL of 19% and 13%, respectively, compared with the typical population value. For subjects on concomitant medication with rifampicin, selumetinib clearance was increased by 85%. A 28% reduction in selumetinib clearance was estimated for subjects coadministered either of the known inhibitors, fluconazole or itraconazole. The population clearance of the median subject not receiving interacting drugs was 13.6 l h -1 . The IIV for this parameter was relatively low, with a CV of 26.1%. A positive correlation between age and V2/F was observed. V2 was estimated to be 42.2 l, with an IIV of 40.9% (CV). The duration of zero-order absorption was 0.27 h (~16 min) for fasted subjects and increased to 2.21 h in the presence of food. The betweensubject variability for this parameter was high, with a CV% of 131%. Additionally, the presence of food was found to have a statistically significant influence on selumetinib exposure, with an estimated 11.6% reduction in bioavailability.
Joint model
The final parent model was modified to incorporate two selumetinib clearance routes, one to represent the N-desmethyl metabolite and the other to represent all other elimination routes (Figure 1 ). The conversion of parent drug to metabolite was assumed to be an irreversible process without back transformation. N-desmethyl metabolite disposition was adequately described by a single compartment with linear elimination. The additional parameters estimated for the metabolite were Fm (fraction of selumetinib converted to the N-desmethyl metabolite) and CLm/F (apparent metabolite clearance). The true fraction of selumetinib converted to the N-desmethyl metabolite is unknown, and thus Fm and V4 (volume of distribution of metabolite compartment) are not identifiable. Therefore, Fm should be interpreted as the ratio of the fraction of selumetinib converted to N-desmethyl metabolite to the volume of distribution of the metabolite compartment (Fm/V4) [18] . Alternative parent-metabolite PK Table 2 A summary of demographic and clinical data for individual studies contributing to the population analysis M (51) M (20) M (23) M (24) M (21) M (72) M (46) M (12) M (330) F (4) F (9) F (2) F (1) F (16) Race Caucasian CL, total drug clearance from plasma; CLm/F, apparent metabolite clearance; CV, coefficient of variation; D1, duration of zero-order absorption; F, relative bioavailability; Fm, fraction of selumetinib converted to metabolite; IIV, interindividual variability; IV, intravenous; JAP, Japanese; Ka, absorption rate constant; m, parameter for metabolite error model; NJAP, non-Japanese Asian; Q, blood flow; RSE, relative standard of error; TAD, time after dose; V2, central volume of distribution; V3, peripheral volume of distribution models with varying assumptions were tested; however, the selected model was preferred [19, 20] . Correlations observed between CL and V2 (r 2 = 0.70) and between Fm and CLm (r 2 = 0.96) were captured within the model using covariance
terms. An additive error model remained adequate for the parent data; however, a proportional error model was found to be more suitable for describing the metabolite residual error. A negative correlation between weight and Fm was evident and accounted for in the determination of Fm/V4 using a fixed exponent of 1, after which no correlation was observable. Box plots of empirical Bayes estimates (EBEs) for Fm indicated differences in Fm from the population value according to degree of hepatic impairment and race. No trends could be detected in the EBEs for CLm/F. Scatter plots showed weak relationships (r 2 ≤ 0.14) between continuous covariates and EBEs for Fm and CLm/F. On formal testing, race and ChildPugh score (1, 2/3) resulted in a statistically significant reduction in the OFV of 26.5 and 65.0, respectively. Only three of eight individuals with a Child-Pugh score of 3 had measurable metabolite concentrations; therefore, these individuals were combined with the group with a Child-Pugh score of 2, and a single coefficient was estimated for the effect of moderate-to-severe liver impairment on Fm. At this stage, the model was updated with data from Studies 78 and 80 to yield the final model, in which Fm is described as a function of weight, race (Japanese and non-Japanese) and Child-Pugh score (FLG1 = score 1, FLG2 = score 2 or 3). No covariate effects were detected for the metabolite clearance. Selumetinib PK parameters have been described earlier.
Final parameter estimates from the simultaneous modelling of parent-metabolite concentration measurements are presented alongside the final parent-only model in Table 3 . The results from performing a bootstrap analysis on the final joint model are also reported in this table. The structural parameters for selumetinib and the magnitude of their respective covariate effects were similar following the addition of a metabolite compartment. Structural parameters within the joint base model for the metabolite were estimated with good precision (RSE%, <20%). The IIV estimated for both Fm and CLm/F were relatively high, with a CV% of 99.1 and 94.7, respectively.
The fraction of selumetinib converted to N-desmethyl metabolite was estimated to be 0.10, which is consistent with the results from previous unreported analyses. For subjects with a hepatic impairment, there was a distinct correlation between Child-Pugh score and ability to form metabolite, with a 34% and 54% reduction in the formation of the N-desmethyl metabolite for mild-to-moderate and severe impairment groups, respectively. Japanese and non-Japanese Asian subjects were estimated to have an increased Fm of 36% and 23%, respectively, compared with the typical population value.
Model evaluation and sensitivity analysis
Individual goodness-of-fit plots indicated that selumetinib PK were well described in both parent and joint models. The joint model also captured metabolite time-concentrations well. Diagnostic plots for the joint model showed good agreement between predicted and observed concentrations for Figure 1 Structure of joint parent-metabolite pharmacokinetic model. CL, total drug clearance from plasma; CLm, clearance of metabolite from plasma Population pharmacokinetics of selumetinib in healthy volunteers each analyte, and no bias could be observed in residuals with time or predicted concentration ( Figure 2 ). This was also the case on examination of the plots stratified by study number. Visual predictive checks (dose corrected) corresponding to the final joint model are shown in Figure 3 . For both selumetinib and N-desmethyl selumetinib, the majority of the observed data points lay within the 90% prediction interval and were symmetrically distributed around the median. Overall, the model diagnostic results suggested that the proposed final model for selumetinib and its N-desmethyl Figure 2 Goodness-of-fit plots for (a) parent and (b) metabolite: observed ln concentrations vs. population and individual predicted ln concentrations, and conditional weighted residuals (CWRES) vs. population predicted ln concentrations and time after dose. Red solid lines represent the line of unity. Blue solid lines represent application of a smoothing line to the data metabolite characterized the observed plasma PK concentrations well.
The results from the sensitivity analysis for significant covariates are presented in Figure 4 . In the presence of food, the C max for selumetinib and N-desmethyl were reduced by 54% and 50%, respectively, which was consistent with the findings from noncompartmental analysis. Impaired liver function resulted in a change in N-desmethyl C max of À34% and À53% for Child-Pugh scores of 1 and 2/3, respectively. A change in N-desmethyl AUC 0-72 of À24% and À40% were simulated for Child-Pugh scores of 1 and 2/3, respectively. Otherwise, changes in exposure (AUC 0-72 /C max ) for selumetinib and N-desmethyl selumetinib (excluding DDIs) were within the range of 82-128% and 78-136%, respectively, of the representative individual. The additional covariates of age, bilirubin level and weight did not appear to have a significant impact on the overall exposure of selumetinib and its metabolite.
Discussion
The population PK models for selumetinib and its N-desmethyl metabolite have been developed using data from 10 phase I clinical studies conducted in healthy subjects and subjects with hepatic or renal impairment.
During model development, a significant food effect was estimated for selumetinib, with a reduction in the rate (0.37 vs. 3.0 h, D1) and extent of absorption (Table 2 ). In agreement with preclinical findings suggesting that selumetinib is metabolized by CYP3A4/5 and CYP2C19, significant DDI effects were estimated for the strong CYP3A inhibitor itraconazole (27% decrease in clearance), strong CYP3A inducer rifampicin (86% increase in clearance) and moderate CYP2C19 inhibitor fluconazole (26% decrease in clearance) in the present analysis. Race is another significant covariate that affects the overall clearance of selumetinib. Japanese and non-Japanese Asian subjects exhibited a 17% and 12% decrease in clearance, respectively, compared with Caucasians. Selumetinib is predominantly metabolized via UDP glucuronosyltransferase (UGT) 1A1 (and 3), and CYP 1A2, 2C19 and 3A4. The potential ethnic differences in each of these pathways [UGT1A1 (allelic variants), CYP2C19 (increased polymorphisms in Japanese and Chinese subjects) and CYP3A4/1A2 (expression lower in Asians by 10-15%)] may provide an explanation for the finding of a reduced selumetinib CL for Asians in the present analysis. Interestingly, Japanese and non-Japanese Asians were estimated to have a 36% and 23% increase, respectively, in the conversion of selumetinib to its N-desmethyl metabolite compared with the typical population value. It should be noted that this could be reflective of a change in Vm rather than Fm -i.e. a decrease in the distribution volume for the metabolite in Asian populations. Of the covariates tested, the strongest influence was observed for bilirubin level, with an estimated 10% reduction in CL for each unit rise in bilirubin level. Child-Pugh score and ALT level were found to be predictors of selumetinib CL during univariate analysis but dropped out as significant explanatory variables as covariate analysis proceeded. It should be noted that on the visual examination of the scatter plot for CL vs. bilirubin, the linear regression line did not describe some of the highest bilirubin values which belonged to individuals in Study 82 with hepatic impairment. Indicators of renal performance (e.g. creatinine clearance) did not come out as significant, which was understandable, given that renal elimination is a minor pathway in selumetinib CL. The positive correlation observed between age and V2 could be explained by consideration of changes in body composition with age and the physiochemical properties of selumetinib. It has been reported that the volume of distribution of lipophilic drugs increases with age [21, 22] . Given that selumetinib is considered a lipophilic drug (with a logP of 3.88), it would be reasonable to see an age effect on V2.
The effects of DDIs, race, food, hepatic performance and dialysis status have already been assessed and quantified through noncompartmental analysis. A sensitivity analysis [23] was undertaken primarily to measure the influence of the additional covariates identified during the current population PK analysis. The changes in selumetinib and Figure 3 Visual predicted checks (dose corrected) for (a) selumetinib and (b) N-desmethyl selumetinib on a log scale axis. Red solid lines represent the simulated median quantile, and the lower and upper solid blue lines represent the simulated 5th and 95th quantiles, respectively. Confidence intervals (95%) for quantiles are shown as dashed lines. Black circles represent the observed data N-desmethyl selumetinib exposure (AUC 0-72 and C max ) observed in the present analysis are considered to be consistent with those observed in individual clinical studies.
In conclusion, the developed population PK model adequately described the selumetinib and N-desmethyl selumetinib time-concentration profiles observed in healthy subjects and those with renal and hepatic impairment. The findings from the present population PK analysis concurred with the results from noncompartmental analyses with respect to DDI, food effects and race. Additional covariates, including body weight, age and bilirubin level, have been identified as influential to selumetinib and N-desmethyl selumetinib disposition. However, based on the results of the sensitivity analysis, these covariates are expected to have minimal clinical impact on overall drug exposure. It should be noted that although the inferences have been made on the basis of data which have largely come from healthy volunteers, a wide range in covariate values were observed among individuals, which gives increased confidence in the results presented and their applicability to the treatment population.
Figure 4
Sensitivity plots representing the effect of covariates on area under the concentration-time curve from zero to 72 h (AUC 0-72 ) or maximum plasma drug concentration (C max ) of selumetinib (A and B) and its metabolite, N-desmethyl selumetinib (C and D), respectively, for a representative adult. Covariates are listed on the y-axis alongside the actual values (5th and 95th percentiles) used for simulation, and the magnitude of effect compared with the representative individual is given on the x-axis. The effect of a covariate is reported as a percentage compared with the base value (i.e. the representative individual, 100%). The dashed vertical line represents the pharmacokinetic parameter value AUC or C max for the representative individual. For continuous covariates, solid black horizontal lines represent the change in exposure expected, given the 5th and 95th percentile of the respective covariate. Changes in exposure from baseline for categorical covariates are marked with black dots
